Browse the corpus

Cangrelor, a potent intravenous antiplatelet agent, has been approved by the U.S. Food and Drug Administration (FDA) for its use in specific patient populations undergoing percutaneous coronary intervention (PCI). The drug's efficacy in reducing thrombotic events during and after PCI is attributed to its unique mechanism of action, pharmacokinetics, and pharmacodynamics. Although cangrelor is generally well tolerated, healthcare professionals must be aware of the potential adverse drug reactions (ADRs), drug interactions, contraindications, and managing overdose related to cangrelor. This therapeutic review aims to provide an in-depth analysis of cangrelor, encompassing its indications, FDA approval, off-label uses, mechanism of action, pharmacokinetics, pharmacodynamics, and ADRs. Moreover, this activity also highlights the crucial role of interprofessional collaboration in enhancing patient outcomes. Objectives: Identify appropriate indications for cangrelor therapy in patients undergoing percutaneous coronary intervention. Apply evidence-based guidelines and best practices when selecting cangrelor as an antiplatelet therapy option. Assess the potential risks and complications related to cangrelor therapy. Screen patients for contraindications, potential drug interactions, and individual risk factors influencing cangrelor therapy. Access free multiple choice questions on this topic.

Severe toxicity related specifically to cangrelor is rare.[35] Nevertheless, some potential toxicity concerns are associated with cangrelor use, including bleeding, allergic reactions, thrombocytopenia, and local site reactions. Data on cangrelor overdose were assessed in a pooled analysis of the CHAMPION trials. The study identified 36 patients who experienced an overdose of cangrelor. In most cases, the cangrelor dose did not exceed 2.5 times the recommended dosage. Notably, only 1 patient who experienced an overdose had a severe bleeding event.[36] Signs and Symptoms of Overdose Common signs and symptoms of cangrelor overdose include bleeding and thrombocytopenia. Managing Overdose Managing cangrelor overdose involves providing supportive care and closely monitoring the patient's condition as no specific antidote is available for the drug. Stop the cangrelor infusion immediately and seek assistance from a rapid response team.[37] Monitor the patient's vital signs, including blood pressure, heart rate, and oxygen saturation. Perform continuous cardiac monitoring to assess for any arrhythmias or changes in the electrocardiogram. Consider platelet transfusion under the guidance of a hematologist in cases of severe bleeding or refractory thrombocytopenia to restore platelet function and aid in clot formation. Consult a toxicologist in severe cases for assistance.

Interdisciplinary collaboration and effective communication among these healthcare professionals are essential to optimize patient outcomes and ensure the safe use of cangrelor. By working together, they can provide comprehensive care, monitor for potential adverse events, and adjust the treatment plan to achieve the best possible results for the patient. When cangrelor is administered to a patient, several disciplines may be involved in treating the patient and managing their condition. The cardiologist plays a central role in the administration of cangrelor, as they are responsible for determining the appropriate indication, dosage, and duration of therapy. In addition, the cardiology team monitors the patient's cardiovascular status, assesses the need for antiplatelet therapy, and evaluates the response to treatment. Clinical pharmacists play a crucial role in ensuring the safe and effective use of cangrelor. They provide medication reconciliation, assess potential drug interactions, recommend appropriate dosing adjustments in patients with renal or hepatic impairment, and educate patients on the medication. Cardiothoracic surgery is required for off-label uses. A hematologist consultation may be necessary for severe bleeding. Pathologist provides valuable input regarding the appropriate laboratory monitoring. Nursing should monitor the patient and inform the team regarding any adverse event. According to the CAMEO registry (Cangrelor in Acute Myocardial Infarction: Effectiveness and Outcomes), considerable variation in the utilization of cangrelor is evident across different hospitals, with only 27% of patients receiving cangrelor and transitioning to an oral P2Y12 inhibitor in adherence to the clinical trial and FDA label. Additionally, over one-third of patients are administered a cangrelor infusion for a duration shorter than what is recommended by the FDA (<2 h). These results have important clinical implications, emphasizing the need for improvement in P2Y12 inhibitor transition for individuals undergoing PCI after experiencing an MI. The strategy suggested is improving the knowledge and understanding of clinicians and pharmacists to facilitate the appropriate utilization and smooth transition of cangrelor to an oral P2Y12 inhibitor.[38]

Additionally, over one-third of patients are administered a cangrelor infusion for a duration shorter than what is recommended by the FDA (<2 h). These results have important clinical implications, emphasizing the need for improvement in P2Y12 inhibitor transition for individuals undergoing PCI after experiencing an MI. The strategy suggested is improving the knowledge and understanding of clinicians and pharmacists to facilitate the appropriate utilization and smooth transition of cangrelor to an oral P2Y12 inhibitor.[38] Consequently, an interprofessional team approach utilizing open communication and shared decision-making among clinicians, including specialists, pharmacists, and toxicologists, is essential to improve patient outcomes related to cangrelor therapy.